Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and immunogenicity of ZR-202-CoV, administered as 2 injections (i.m) at 28 days apart in adult subjects 60 years of age and above.
Epistemonikos ID: a3ac258dcdc97eba1d02600c46ac890fed3d6b41
First added on: Apr 07, 2022